Neuroscience R&D newsroom

Bill Martin is the Global focus area head, Neuroscience, and is a member of the company’s Group Operating Committee. He leads a dedicated team focused on the discovery and development of a precision neuroscience pipeline of transformative treatments for individuals grappling with serious neuropsychiatric and neurodegenerative disorders. Building on Johnson & Johnson’s nearly seven-decade legacy in neuroscience, Bill’s team is driving a differentiated portfolio of new and innovative therapies, each targeting a subpopulation of patients.

Peter Fang is the Worldwide Vice President, Neuroscience Global Commercial Strategy Organization for Johnson & Johnson. Working closely with Research & Development, he is responsible for developing and driving commercial strategies for the Neuroscience portfolio and pipeline within neuropsychiatric, neurodegenerative and autoantibody-driven diseases of the nervous system. Peter oversees Strategic Marketing, Market Access, Medical Affairs and Strategic Analytics teams that support the Global Neuroscience business.

Fiona Elwood, Ph.D., has extensive experience in neuroscience and neurodegenerative research and development, a passion for bringing relief to patients and their caregivers, and dedication to scientific excellence and exceptional teamwork. She brings deep expertise in molecular mechanisms of neurodegeneration, including in tau biology, and precision approaches to accelerate the drug discovery and development cycle.

Wayne Drevets, M.D., Neuropsychiatry Disease Leader, Neuroscience, leads a cross-functional team in the development of Johnson & Johnson’s industry-leading portfolio of novel therapeutics in mood and psychotic disorders. In this capacity, Wayne oversees the strategy, conception, and execution of a program he helped build at Johnson & Johnson for developing novel treatments for major depressive disorder, bipolar disorder, and schizophrenia from discovery through late-development phases.